Jasper Therapeutics(US:JSPR) Prnewswire·2025-10-03 15:25Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. for alleged violations of federal securities laws, encouraging affected investors to contact them regarding their legal options [1][3]. Group 1: Allegations Against Jasper - The complaint alleges that Jasper and its executives made false or misleading statements and failed to disclose critical information regarding their manufacturing processes and product suitability for clinical trials [3]. - Specific allegations include a lack of necessary controls for third-party manufacturers, which increased the risk of confounding study results and negatively impacted the regulatory and commercial prospects of Jasper's products, particularly briquilimab [3]. - The complaint also suggests that these failures led to overstated business and financial prospects, resulting in materially false public statements by the defendants [3]. Group 2: Recent Developments - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, which affected study results and led to the halting of the ETESIAN Study and the development of briquilimab for asthma and SCID [4]. - Following this announcement, Jasper's stock price dropped by $3.73 per share, or 55.1%, closing at $3.04 per share [4]. Group 3: Legal Proceedings - Investors who purchased Jasper securities between November 30, 2023, and July 3, 2025, are reminded of the November 18, 2025, deadline to seek the role of lead plaintiff in the federal securities class action against the company [1][5]. - The lead plaintiff is defined as the investor with the largest financial interest who is adequate and typical of class members, overseeing the litigation on behalf of the class [5].